Login
From:
jamanetwork.com
(Uncensored)
subscribe
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial | Dementia and Cognitive Impairment | JAMA | JAMA Network
https://jamanetwork.com/journals/jama/fullarticle/2807533
links
backlinks
This randomized clinical trial examines the efficacy and adverse effects of donanemab, a monoclonal antibody designed to clear brain amyloid plaque, among patients with early symptomatic Alzheimer disease.
Roast topics
Find topics
Find it!
